Objective
Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUT’HIVAC consortium gathers knowledge’s and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUT’HIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU® candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUT’HIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.
Fields of science
- medical and health scienceshealth sciencesinfectious diseasesmalaria
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Call for proposal
FP7-HEALTH-2009-single-stage
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
75252 Paris
France
See on map
Participants (17)
93053 Regensburg
See on map
08916 Barcelona
See on map
33520 Tampere
See on map
10117 Berlin
See on map
Participation ended
SW17 0RE London
See on map
Participation ended
L 14 Lima
See on map
75794 Paris
See on map
W1B 1AL London
See on map
75654 Paris
See on map
Maputo
See on map
Participation ended
69002 Lyon
See on map
69002 Lyon
See on map
93053 Regensburg
See on map
L04 Lima
See on map
SW7 2AZ London
See on map
75013 Paris
See on map
WC1E 6BT London
See on map